Securities code: Shanghai Pharmaceuticals Holding Co.Ltd(601607) securities abbreviation: Shanghai Pharmaceuticals Holding Co.Ltd(601607) No.: pro 2022029
Shanghai Pharmaceuticals Holding Co.Ltd(601607)
Announcement on the renewal of accounting firm
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents. Important note: the company plans to renew the appointment of PricewaterhouseCoopers Zhongtian Certified Public Accountants (special general partnership) as the audit institution in 2022. 1、 Basic information of the accounting firm to be renewed (I) institutional information
1. Basic information
PricewaterhouseCoopers Zhongtian was formerly known as PricewaterhouseCoopers Dahua certified public accountants, which was established on March 28, 1993. With approval, it was renamed PricewaterhouseCoopers Zhongtian certified public accountants Co., Ltd; Approved by the Ministry of Finance Cai Kuai Han [2012] No. 52 on December 24, 2012, it was transformed into PricewaterhouseCoopers Zhongtian Certified Public Accountants (special general partnership) on January 18, 2013. The registered address is room 01, unit 507, DBS building, 1318 Shanghai Lujiazui Finance & Trade Zone Development Co.Ltd(600663) Ring Road, China (Shanghai) pilot free trade zone.
PricewaterhouseCoopers Zhongtian is a member organization of PricewaterhouseCoopers international network. It has the practice certificate of accounting firm and the qualification to engage in the audit business of H-share enterprises. At the same time, it is also an accounting firm with the qualification of securities and futures related business approved by the Ministry of Finance and the CSRC. In addition, PwC Zhongtian is also registered with us PCAOB (American public company accounting oversight board) and UK FRC (UK financial reporting office) to engage in relevant audit business. PwC Zhongtian has rich experience in securities business and good professional service ability. The chief partner of PricewaterhouseCoopers Zhongtian is Li Dan. As of December 31, 2021, the number of PWC Zhongtian partners was 257 and the number of certified public accountants was 1401, including 346 certified public accountants who have signed the audit report of securities service business since 2013.
In the latest fiscal year (2020) audited by PwC Zhongtian, the total revenue was RMB 6.115 billion, the audit revenue was RMB 5.692 billion and the securities business revenue was RMB 2.861 billion.
The total number of audited A-share listed companies in China’s real estate industry and transportation industry is RMB 60.84 billion, and the number of audited A-share listed companies in China’s real estate industry and transportation industry is RMB 10.05 billion. The number of audited A-share listed companies in China’s real estate industry and transportation industry is RMB 10.05 billion, respectively.
2. Investor protection ability
In terms of investor protection ability, PwC Zhongtian has taken out occupational insurance in accordance with relevant laws and regulations. The sum of the cumulative compensation limit of occupational insurance and occupational risk fund exceeds 200 million yuan. The withdrawal of occupational risk fund or the purchase of occupational insurance comply with relevant regulations. PwC Zhongtian has not undertaken civil liability in relevant civil proceedings due to its practice in recent three years. 3. Integrity record
PricewaterhouseCoopers Zhongtian and its employees have not been subject to criminal punishment, administrative punishment, self-discipline supervision measures and disciplinary sanctions of stock exchanges, industry associations and other self-discipline organizations for practicing behavior in recent three years; PwC Zhongtian has not been subject to the administrative supervision measures of the CSRC and its dispatched offices due to its practice. The four junior employees of PricewaterhouseCoopers Zhongtian received a warning letter from Shanghai Securities Regulatory Bureau in 2019 because their personal investment behavior violated the relevant provisions on independence. The above personal behavior did not affect the effectiveness of PricewaterhouseCoopers Zhongtian quality control system or the practice quality of audit projects. The four employees subsequently resigned from PricewaterhouseCoopers Zhongtian. According to relevant laws and regulations, the above administrative supervision measures will not affect PwC Zhongtian to continue to undertake or execute securities service business and other businesses. (II) project information 1 Partner of basic information project and signed certified public accountant: Liu Wei, a practicing member of the Institute of certified public accountants, has been a certified public accountant since 2003. He has been engaged in the audit of listed companies since 2000. He has provided audit services for Shanghai Pharmaceuticals Holding Co.Ltd(601607) from 2011 to 2015 and from 2018 to 2021. He has been practicing at PricewaterhouseCoopers Zhongtian since 2002 and has signed the audit reports of 8 listed companies in recent three years. Project quality review partner: Meng Jiangfeng, a certified public accountant of the Hong Kong Institute of certified public accountants, has been a certified public accountant since 2000, engaged in the audit of listed companies since 1997, and provided audit for Shanghai Pharmaceuticals Holding Co.Ltd(601607) since 2019
Since 1997, he has been practicing in PricewaterhouseCoopers Zhongtian and has reviewed the audit reports of 9 listed companies in the past three years. Signing CPA: Zhou Linjie, a practicing member of the Institute of certified public accountants, has been a certified public accountant since 2013, engaged in the audit of listed companies since 2010, provided audit services for Shanghai Pharmaceuticals Holding Co.Ltd(601607) since 2010, practiced in PwC Zhongtian since 2010, and has signed the audit report of one listed company in recent three years. 2. Integrity record
With regard to PwC Zhongtian’s proposed employment as the company’s audit institution in 2022, Mr. Liu Wei, the project partner and the signing certified public accountant, Mr. Meng Jiangfeng, the quality review partner and Ms. Zhou Linjie, the signing certified public accountant, have not been subject to any criminal and administrative punishment in the past three years, have not been subject to the administrative supervision and management measures of the securities regulatory authority due to their practice, and have not been subject to the supervision and management measures of the stock exchange Self regulatory measures and disciplinary actions of self regulatory organizations such as industry associations. 3. Independence
As for PwC Zhongtian to be employed as the company’s auditor in 2022, there is no situation that may affect the independence of PWC Zhongtian, Mr. Liu Wei, the project partner and the signing certified public accountant, Mr. Meng Jiangfeng, the quality review partner and Ms. Zhou Linjie, the signing certified public accountant. 4. Audit fees
The audit service charge of PWC Zhongtian is determined by both parties through negotiation according to the audit workload and the principle of fairness and reasonableness. In 2021, the company and some subsidiaries incurred a total audit fee of 24.5 million yuan (including relevant prepaid expenses and taxes), and the internal control audit fee was 1.6 million yuan (including relevant prepaid expenses and taxes). In 2022, the audit fee will be submitted to the general meeting of shareholders to authorize the board of directors to negotiate with PwC Zhongtian according to the actual business situation of the company. 2、 Procedures for the proposed renewal of the accounting firm (I) the 18th Audit Committee of the 7th session of the company considered and approved the proposal on paying audit fees and renewing the appointment of the accounting firm in 2021, and considered that PwC Zhongtian holds securities related business qualifications, has strong professional ability and investor protection ability, has rich audit experience, has independence and good faith, Be competent in the audit of the company;
（2） The 29th meeting of the seventh board of directors and the 20th meeting of the seventh board of supervisors of the company have deliberated and adopted the proposal on paying audit fees in 2021 and renewing the appointment of accounting firms; The independent directors of the company have approved and issued independent opinions on the renewal of the accounting firm in advance, and confirmed that PwC Zhongtian meets the company’s future audit needs in terms of professional qualification, professional ability, investor protection ability, independence and integrity, and the relevant review procedures are properly and fully performed; （3） The renewal of the accounting firm needs to be submitted to the general meeting of shareholders of the company for deliberation and effective from the date of deliberation and approval by the general meeting of shareholders.
It is hereby announced.
Shanghai Pharmaceuticals Holding Co.Ltd(601607) board of directors
March 30, 2022
